PBC treatment: the present and future. Maggie Bassendine Professor of Hepatology
|
|
- Nelson Barrett
- 6 years ago
- Views:
Transcription
1 PBC treatment: the present and future Maggie Bassendine Professor of Hepatology
2 Primary biliary cirrhosis 20-25yrs OLT/ Death Symptoms: Fatigue, itching, jaundice Autoimmune disease: Focal small bile duct damage Autoreactivity: Antimitochondrial &/or antinuclear antibodies Autoreactivity preceeds clinical disease Environmental factors Polymorphic genes Refs: Mitchison HC et al. Hepatology 1986;6: , Metcalf J et al. Lancet 1996;384:
3 PBC treatment: the present Specific therapy- Ursodeoxycholic acid (UDCA) Treatment of symptoms Liver transplantation
4 Ursodeoxycholic acid (UDCA) China was the first country utilizing bear bile in traditional medicinal products (Tang Dynasty, 659 A.D). UDCA was found to be the primary bile acid produced in the liver of bears, compared to 3% of bile acid pool in humans. Japanese scientists succeeded in chemically synthesizing UDCA in 1955 UDCA is well tolerated After oral administration it undergoes an enterohepatic circulation and, in a dose of 13-15mg/kg/day, it becomes the predominant bile acid in human serum and bile.
5 Ursodeoxycholic acid (UDCA) UDCA is the only FDA drug licensed to treat patients with PBC. UDCA is recommended by the practice guidelines of both the European and the American Associations for the Study of Liver Diseases for PBC patients with abnormal liver biochemical values The dose of UDCA is important 13 to15 mg/kg/day Long-term treatment with UDCA can improve liver biochemistry and survival free of liver transplantation EASL Clinical Practice Guidelines: Management of cholestatic liver diseases J Hepatol 2009;51:237-67
6 Ursodeoxycholic acid (UDCA) UDCA responders UDCA non-responders Patients with a decrease in alkaline phosphatase of 40% or a decrease to normal at one year have a prognosis similar to that of an age-matched healthy population Absence of a biochemical response to UDCA has prognostic implications Adjuvant therapy may be considered in UDCA non-responders (± 40%) Ref: Pares A et al. Gastro 2006;130:715-20
7 Primary biliary cirrhosis
8 Primary biliary cirrhosis: disease progression In PBC the slowly progressive destruction of small bile ducts is accompanied by an increase in liver fibrosis, leading to biliary cirrhosis over a period of years UDCA may be more effective when initiated at the earlier stages of disease Ref: Poupon R. J Hepatol.2010;52:
9 PBC treatment: the present Treatment of symptoms: Pruritus: Cholestyramine, Rifampicin, Naltrexone Fatigue: Multifactorial etiology Modafinil can be tried EASL Clinical Practice Guidelines: Management of cholestatic liver diseases J Hepatol 2009;51: Liver transplantation: The only effective treatment for those with end-stage disease The model for end-stage liver disease (MELD) formula can be used to predict short-term survival a MELD score > 16 indicates a survival benefit from transplantation PBC patients should be considered by a transplant centre when the serum bilirubin level approaches 100mmol/l (6mg/100ml)
10 Definition of biochemical response to treatment with UDCA Angulo et al. (1999) ALP < 2 times ULN Pares et al (2006) ALP < 40% from baseline or to normal value Corpechot et al. (2008) ALP < 3 times ULN, AST < 2 times ULN, Bilirubin < 1.0 mg/dl Kuiper et al. (2009) Normal bilirubin and albumin (if one or both were abnormal before treatment); Normal bilirubin or albumin (if both were abnormal before treatment) Therapeutic trials with a new agent should target patients with incomplete biochemical response after 3-6 months of treatment with an adequate dose of UDCA. Complete biochemical response should be defined as ALP < 3 times ULN, AST < 2 times ULN, and bilirubin < 1.0 mg/dl (Corpechot et al. 2008) All therapeutic trials should compare UDCA with or without the new therapy. AASLD endpoints conference: Design and endpoints for clinical trials in primary biliary cirrhosis Silveira MG et al. Hepatology 2010;52:349-59
11 AASLD endpoints conference: Design and endpoints for clinical trials in primary biliary cirrhosis PBC affects fewer than 200,000 people in the United States and has been designated by the FDA as an orphan disease. If new therapeutic trials are targeted toward patients who are incomplete biochemical responders to UDCA, then the pool of potential study subjects drops to less than 40,000 nationwide. It is unavoidable that future clinical trials will require the collaboration of a large number of centres. A consortium of centres focused upon the study of PBC, including expertise in pathology, genetics, biliary physiology, immunology, biostatistics, and liver transplantation is urgently needed to spearhead and drive clinical trials of high quality. Silveira MG et al. Hepatology 2010;52:349-59
12 PBC treatment: the future Multicentre controlled trials comparing UDCA with combination therapy UDCA + immunosuppression [Budesonide] UDCA + FXR agonist UDCA + PPAR agonist New therapeutic targets eg IL12 pathway
13 Budesonide combined with UDCA: A 3 year prospective randomised trial PBC patients (n = 77, histological stage I-III), were randomised to Budesonide 6 mg/d + UDCA 15 mg/kg/d (n = 41) or UDCA monotherapy (n = 36) Histological stage improved in 22% of combination therapy but deteriorated in 20% of UDCA monotherapy Fibrosis decreased in 25% of combination therapy but increased in 70% of UDCA monotherapy Alkaline Phosphatase decreased in both arms Bilirubin rose in UDCA monotherapy arm but was stable in combination therapy (p = 0.002) Ref: Rautianen H et al. Hepatology 2005;41:747
14 Farnesoid-X X Receptor Agonists: a New Class of Drugs for the Treatment of PBC? An International Study Evaluating the Addition of INT-747 (Obeticholic Acid) to Ursodeoxycholic Acid Andrew Mason, Velimir Luketic, Keith Lindor, Gideon Hirschfield, Stuart Gordon, Marlyn Mayo, Kris Kowdley, Albert Parés, Michael Trauner, Erin Castelloe, Cathi Sciacca, Tessa Beecher Jones, Mark Pruzanski, David Shapiro and the INT-747 PBC Investigator Group U. Alberta, Virginia Commonwealth U., Mayo Clinic, U. Toronto, Henry Ford Clinic, U. Texas SW, Virginia Mason Med Center, U. Barcelona, U. Graz, Intercept Pharmaceuticals. EASL 2010
15 INT-747: 6α-Ethyl 6 Chenodeoxycholic Acid ( Obeticholic Acid) INT 747 6α ethyl chenodeoxycholic acid CDCA chenodeoxycholic acid UDCA ursodeoxycholic acid FXR EC 50 (agonist) µm 8.66 µm No activity ~ 2 log FXR agonism Pelliciari R. J.Med.Chem 2002
16 INT-747: Addition to UDCA Dose Response Study Design UDCA N=35/group Placebo INT mg Baseline Follow-Up INT mg INT mg Screening Baseline 1-4 weeks predose Double Blind Phase 12 weeks Follow-Up Phase 2 weeks
17 INT-747: Addition to UDCA 8 Countries, 33 Centers (USA: 56%, Canada: 26%, Europe: 18%)
18 INT-747: Addition to UDCA Alkaline Phosphatase % 0 Day Follow up % Placebo (n=37) 10 mg (n=37) 25 mg (n=42) 50 mg (n=25) 30 Day 85 p< all doses 40
19 INT-747: Addition to UDCA Principal AE = pruritus % Pruritus Severity Mild Moderate Severe Discontinuations Placebo 10mg 25mg 50mg 40 % Placebo 10mg 25mg 50mg 0 Placebo 10mg 25mg 50mg Overall 10mg good efficacy & acceptably tolerated Phase 3 studies
20 Use of PPAR agonists (fibrates) in PBC Fukuo Y et al Nippon Ika Daigola Zasshi 1996;63:424 Iwasaki S et al Hepatol Res 1999;16:12 Miyaguchi S et al. Hepato-Gastoenterol. 2000;47:1518 Nakai S et al. Am J Gastro. 2000;95:326, Ohmoto K et al. Liver 2001;21:223 Kurihara T et al. Am J Gastro 2002;97:212 Yano K et al. Am J Gastro. 2002;97:41 Bezafibrate or Fenofibrate have been reported to be added to UDCA non-responders in >95 PBC patients with significant decrease in serum Alkaline Phosphatase levels Kanda T et al. J Gastroenterol. 2003;38:573 Itakura J et al. Hepatol Res ;29:216 Dohmen K et al. WJG 2004;10:894 Akbar SM et al J Gastroenterol. 2005;40:157 Nakamuta M et al. J Gastroenterol 2005;40:546 Ohmoto K et al. J Gastroenterol. 2006;41:502 Iwasaki S et al. Hepatol Res. 2008;38:557 Walker LJ et al. Hepatology 2009;49: Hassan R et al. J Clin Gastroenterol 2010;44:371 Ref: Ohira H et al AJG
21 Adjuvant therapy in PBC: Effects of adding Fenofibrate in UDCA non-responders Fenofibrate ( mg daily) was added to UDCA in 16 patients with lack of biochemical response These PBC patients showed significant falls in ALP (p=0.0016) (89% falling to within the normal range) and IgM (p=0.0015) Ref: Walker LJ et al. Hepatology 2009;49:
22 Genome-wide association studies in PBC In the combined Canadian and Italian data, IL12A and IL12RB2 were the strongest non- HLA associations. In the mouse model of PBC, signalling by way of IL-12p40 is an essential requirement for the development of autoimmune cholangitis The findings suggest involvement of the IL12 signalling pathways in the pathogenesis of PBC Refs: Liu X et al. Nature Genetics 2010;42:658, Yoshida K et al. Hepatology 2009;50:1347
23 IL12 signalling pathway (type-1 cytokine/receptor interactions) relevant for immunity against intracellular bacteria Manipulation of the IL12/IFNγ pathway may enable PBC to be cured in future Ref: Lamas DA et al. Int. J of Exp. Pathol. 2002,83:1-20
24 PBC treatment: the present and future
Diagnosis and Management of PBC
Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in
More informationOcaliva (obeticholic acid tablets)
Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ocaliva (obeticholic acid) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ocaliva (obeticholic acid) Prime Therapeutics will review Prior Authorization
More informationHangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam
Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary
More informationNew insights in pathogenesis and therapy of primary biliary cholangitis. Keith D. Lindor Dean Professor of Medicine
New insights in pathogenesis and therapy of primary biliary cholangitis Keith D. Lindor Dean Professor of Medicine OUTLINE PBC Epidemiology Diagnosis Treatment Incidence of PBC and PSC Trends Boonstra
More informationRisk stratification in PBC
Risk stratification in PBC Christophe Corpechot Reference Center for Inflammatory Biliary Diseases Saint-Antoine hospital, Paris, France What is currently known (background) PBC : chronic, progressive
More informationTREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)
TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC) URSO not indicated Therapy for PBC Difficulties Etiology is uncertain Therapies are based on ideas regarding pathogenesis Present medical therapies have a limited
More informationSingle Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785
Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785 Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment
More informationAutoimmune and cholestatic liver diseases
Autoimmune and cholestatic liver diseases Prof. Tom Hemming Karlsen Research Institute of Internal Medicine & Department of Transplantation Medicine University of Oslo & Oslo University Hospital, Norway
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationHepatic Transporter Proteins involved in Bile Formation
Bile salt synthesis Hepatic Transporter Proteins involved in Bile Formation Basolateral membrane transporter proteins fx: NTCP uptake of bile salts OATP bulky organic anions Canalicular membrane transporter
More informationEfficacy and Safety of Seladelpar in Primary Biliary Cholangitis 52-Week Analysis of a Dose-Ranging Phase 2 Study
Efficacy and Safety of Seladelpar in Primary Biliary Cholangitis 52-Week Analysis of a Dose-Ranging Phase 2 Study Bowlus CL, Neff G, Aspinall R, Galambos M, Goel A, Hirschfield G, Kremer AE, Mayo MJ, Swain
More informationObeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope Background: April 21, 2016 Primary biliary cholangitis
More informationChronic Cholestatic Liver Diseases
Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research
More informationPrimary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS
Primary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS Nikolaos T. Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD Associate Professor and Chief, Division of Gastroenterology and Hepatology
More informationPBC features and management in the era of UDCA and Budesonide
PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More
More informationDisclosure/Conflict of Interest Statement
Farnesoid-X Receptor Agonists: a New Class of Drugs for the Treatment of PBC? An International Study Evaluating the Addition of Obeticholic Acid (INT-747) to Ursodeoxycholic Acid An International Study
More informationOverview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN
Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN 2012 Annual Conference PSC Partners Seeking a Cure May 5, 2012 Primary Sclerosing Cholangitis Multifocal
More informationTABLE OF CONTENTS SYMPOSIUM AGENDA. Diagnosis, Stratification of Risk, and Initial Treatment in PBC
PBC Novel Pathways for Treatment of Cholestatic Liver Disease TABLE OF CONTENTS Faculty Biographies SYMPOSIUM AGENDA Introduction Kris V. Kowdley, MD Diagnosis, Stratification of Risk, and Initial Treatment
More informationAESOP Overview and Inclusion/Exclusion Criteria Richard Pencek, PhD
747-207 AESOP Overview and Inclusion/ Criteria Richard Pencek, PhD Sr Director, Clinical Research, Intercept Pharmaceuticals, Inc. 2 PSC Forum 2 AESOP: A Phase 2 Randomized, Placebo-Controlled Trial, Dose-Finding
More informationHépatopathies auto-immunes
16 ème Journée d'automne Lausanne, le 19 octobre 2017 Hépatopathies auto-immunes Nurullah Aslan et Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction
More informationCurrent Concepts in the Management and Treatment of PBC & PSC
Current Concepts in the Management and Treatment of PBC & PSC Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London A family affair? Central vein Hepatocytes
More informationWhere a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid Hirschfield, Gideon; Mason, Andrew; Luketic, Velimir; Lindor, Keith; Gordon, Stuart
More informationPrimary biliary cholangitis
A guide to Primary biliary cholangitis Miss Jennifer Hayden, Autoimmune Liver Disease Clinical Nurse Specialist Professor Gideon M Hirschfield, Professor and Consultant Transplant Hepatologist Centre for
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis What is primary biliary cholangitis? Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease. When a person has PBC, the immune
More informationProgram Disclosure. This activity is supported by an educational grant from Intercept Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership
More informationOCALIVA (obeticholic acid) oral tablet
OCALIVA (obeticholic acid) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationSubject: Obeticholic Acid (Ocaliva ) Tablet
09-J2000-65 Original Effective Date: 09/15/16 Reviewed: 07/11/18 Revised: 08/15/18 Subject: Obeticholic Acid (Ocaliva ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationProlonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis
American Journal of Gastroenterology ISSN 0002-9270 C 2004 by Am. Coll. of Gastroenterology doi: 10.1111/j1572-0241.2004.04047.x Published by Blackwell Publishing Prolonged Follow-Up of Patients in the
More informationShifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity
Overview Shifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity In this video series, Kris Kowdley, MD, and Seth Sclair, MD, share insight into changes in the management of patients with primary
More informationPrimary biliary cholangitis (PBC), previously known as primary
Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis Runalia Bahar, MD, Kimberly A. Wong, MD, Chung H. Liu, and Christopher L. Bowlus, MD Dr Bahar is a hospitalist
More informationHow the concept of biochemical response influenced the management of primary biliary cholangitis over time
ORIGINAL ARTICLE How the concept of biochemical response influenced the management of primary biliary cholangitis over time W.J. Lammers 1 *, M. Leeman 1, C.I.J. Ponsioen 2, K. Boonstra 2, K.J. van Erpecum
More informationACG Clinical Guideline: Primary Sclerosing Cholangitis
ACG Clinical Guideline: Primary Sclerosing Cholangitis Keith D. Lindor, MD, FACG 1, Kris V. Kowdley, MD, FACG 2, and M. Edwyn Harrison, MD 3 1 College of Health Solutions, Arizona State University, Phoenix,
More informationCholestatic Liver Diseases: Update on Diagnosis and Management. Cholestatic Liver Diseases: Location of Injury Determines Phenotype
Cholestatic Liver Diseases: Update on Diagnosis and Management R. Todd Stravitz, M.D. Hume-Lee Transplant Center Section of Hepatology Virginia Commonwealth University Cholestatic Liver Diseases: Location
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationPrimary Biliary Cirrhosis
Primary Biliary Cirrhosis What is Primary Biliary Cirrhosis? Primary biliary cirrhosis (PBC) is a chronic liver disease resulting from progressive destruction of the bile ducts in the liver called the
More informationPresentation and mortality of primary biliary cirrhosis in older patients
Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET
More informationIn primary biliary cholangitis (PBC), progression
HEPATOLOGY COMMUNICATIONS, VOL. 2, NO. 6, 2018 Clinical Application of the GLOBE and United Kingdom-Primary Biliary Cholangitis Risk Scores in a Trial Cohort of Patients With Primary Biliary Cholangitis
More informationImproving the Lives of Patients with Liver Diseases
Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and
More informationObeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks Evidence Report July 26, 2016 Institute for Clinical and Economic
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationHigh dose UDCA in the Treatment of Primary Sclerosing Cholangitis. Falk Meeting,Freiberg2006 Dr RW Chapman John Radcliffe Hospital Oxford,UK
High dose UDCA in the Treatment of Primary Sclerosing Cholangitis Falk Meeting,Freiberg2006 Dr RW Chapman John Radcliffe Hospital Oxford,UK Specific Medical Therapy for PSC Immunosuppressants -prednisolone
More informationMorning Report Presentation. Sarah Hughes, MD January 11, 2005
Morning Report Presentation Sarah Hughes, MD January 11, 2005 Primary Biliary Cirrhosis! PBC is a chronic, progressive, cholestatic liver disease of unknown cause that usually affects middle-aged women
More informationLiver Disease That Presents with Jaundice (PBC, Alcohol and Drugs): Diagnosis and Patient Management. Emma Pham, PA-C
Liver Disease That Presents with Jaundice (PBC, Alcohol and Drugs): Diagnosis and Patient Management Emma Pham, PA-C Case: JL (jaundiced lady) A 72 year old woman presents to her primary care provider
More informationPrimary Sclerosing Cholangitis Medical Management
Primary Sclerosing Cholangitis Medical Management Kapil Chopra M.D. Assistant Professor of Medicine Division of Transplant Medicine Mayo Clinic Arizona PSC Primary sclerosing cholangitis is a progressive
More informationPRIMARY BILIARY CHOLANGITIS: DIAGNOSIS AND MANAGEMENT Project ID:
ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint
More informationTitle: Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA
Title: Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA Authors: Weijia Duan, Xiaojuan Ou, Xiaoming Wang, Yu Wang, Xinyan
More informationMY DISCUSSION GUIDE. Personalize your treatment plan for primary biliary cholangitis (PBC).
I am not on OCALIVA (obeticholic acid) MY DISCUSSION GUIDE Personalize your treatment plan for primary biliary cholangitis (PBC). This guide is not intended to replace the advice of your healthcare team.
More informationPrimary biliary cirrhosis (PBC) is an autoimmune
Early Biochemical Response to Ursodeoxycholic Acid and Long-Term Prognosis of Primary Biliary Cirrhosis: Results of a 14-Year Cohort Study Li-Na Zhang, 1,2 * Tian-Yan Shi, 1,2 * Xu-Hua Shi, 1,2 Li Wang,
More informationManagement of cholestatic diseases Today and tomorrow
12th Paris Hepatology Conference Management of cholestatic diseases Today and tomorrow Paris 15 January 2019 U. Beuers Department of Gastroenterology & Hepatology Tytgat Institute for Liver and Intestinal
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationPrimary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study
LINDOR ET AL. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases Keith D. Lindor 1, Christopher L. Bowlus 2, James Boyer 3, Cynthia Levy 4,
More informationKa-Shing Cheung, MBBS, MPH 1, Wai-Kay Seto, MD 1,2, James Fung, MD 1,2, Ching-Lung Lai, MD 1,2 and Man-Fung Yuen, MD, PhD 1,2
Citation: (2017) 8, e100; doi:10.1038/ctg.2017.23 Official journal of the American College of Gastroenterology www.nature.com/ctg Prognostic Factors for Transplant-Free Survival and Validation of Prognostic
More informationTitle: stratification and treatment of primary biliary cholangitis. Authors: Javier Martínez, Lara Aguilera, Agustín Albillos
Title: Risk stratification and treatment of primary biliary cholangitis Authors: Javier Martínez, Lara Aguilera, Agustín Albillos DOI: 10.17235/reed.2018.5662/2018 Link: PubMed (Epub ahead of print) Please
More informationDrug Design, Development and Therapy
Drug Design, Development and Therapy open access to scientific and medical research Open Access Full Text Article Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary
More informationCost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid
Alimentary Pharmacology and Therapeutics Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid K. M. Boberg*,, T. Wisløff, K. S. Kjøllesdal, H. Støvring & I.
More information21/07/2017. Update on Autoimmune Biliary Disease. Changing Role of Liver Biopsy in PBC and PSC. Primary Biliary Cirrhosis Cholangitis
Primary Biliary Cirrhosis Cholangitis Update on Autoimmune Biliary Disease Changing Change in Nomenclature for PBC : From Cirrhosis to Cholangitis (EASL Panel, Beuers et al J Hepatol Nov 2015, Gut Nov
More informationMY DISCUSSION GUIDE. Get the most out of your OCALIVA treatment.
PBC I am currently taking OCALIVA (obeticholic acid) MY DISCUSSION GUIDE Get the most out of your OCALIVA treatment. This guide is not intended to replace the advice of your healthcare team. All decisions
More informationOverview of PSC Making the Diagnosis
Overview of PSC Making the Diagnosis Tamar Taddei, MD Assistant Professor of Medicine Yale University School of Medicine Overview Definition Epidemiology Diagnosis Modes of presentation Associated diseases
More informationPrimary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants
Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic
More informationPrognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score
pissn 2287-2728 eissn 2287-285X Original Article Clinical and Molecular Hepatology 2012;18:375-382 Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune
More informationWELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here.
WELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here. Photograph of an actual patient What is OCALIVA? OCALIVA is a prescription medicine used to
More informationA COMPANY INSPIRED BY REGENERATION
OUR FOCUS A COMPANY INSPIRED BY REGENERATION MEET ALLY, a teacher, mother and motorcycle enthusiast with primary biliary cholangitis*(pbc), a rare and potentially fatal non-viral liver disease. OUR FOCUS
More informationWelcome and Introduction
Welcome and Introduction Henry C. Bodenheimer, Jr, MD Professor of Medicine Albert Einstein College of Medicine Chairman, Department of Medicine Beth Israel Medical Center New York, New York Introduction
More informationTreatment of Chronic Cholestasis: What We Know and What We Will Know?
REVIEW Treatment of Chronic Cholestasis: What We Know and What We Will Know? James L. Boyer HISTORICAL PERSPECTIVES For many years, the treatment of cholestatic liver disease was limited to surgical relief
More informationInterface hepatitis in PBC: Prognostic marker and therapeutic target
Interface hepatitis in PBC: Prognostic marker and therapeutic target Raoul Poupon Service d Hépatologie, Hôpital Saint-Antoine, Paris Faculté de Médecine Pierre & Marie Curie, Paris Key features of
More informationTowards Precision Medicine in Primary Biliary Cholangitis
Riunione Monotematica A.I.S.F. 2016 THE FUTURE OF LIVER DISEASES: Beyond HCV is there a role for the hepatologist? 14 th October 2016 Towards Precision Medicine in Primary Biliary Cholangitis Marco Carbone,
More informationWELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here.
WELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here. Photograph of an actual patient. What is OCALIVA? OCALIVA (obeticholic acid) is a prescription
More informationKey Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto
Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis
More informationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Original Article A -Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis F. Nevens, P. Andreone, G. Mazzella, S.I. Strasser, C. Bowlus, P. Invernizzi, J.P.H. Drenth, P.J. Pockros, J. Regula,
More informationTratamiento endoscópico de la CEP. En quien como y cuando?
Tratamiento endoscópico de la CEP. En quien como y cuando? Andrés Cárdenas, MD, MMSc, PhD, AGAF, FAASLD GI / Liver Unit, Hospital Clinic Institut de Malalties Digestives i Metaboliques University of Barcelona
More informationNoncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis
Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids Cholestasis Biochemical hallmark Impaired bile flow from liver to small intestine Alkaline phosphatase is primary
More informationChild-Pugh Class B or C or Patients with a Prior Decompensation Event a 5 mg once daily 5 mg once weekly. Compensated Child- Pugh Class A
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OCALIVA safely and effectively. See full prescribing information for OCALIVA. OCALIVA (obeticholic
More informationGEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE
GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE Kalliopi Azariadis 1, Nikolaos K. Gatselis 1, Kalliopi Zachou 1, Vasiliki Lygoura 1, Pinelopi Arvaniti 1, Eirini I. Rigopoulou 1, Georgia
More informationResearch Article Incidence, Mortality, and Predictive Factors of Hepatocellular Carcinoma in Primary Biliary Cirrhosis
Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2013, Article ID 168012, 8 pages http://dx.doi.org/10.1155/2013/168012 Research Article Incidence, Mortality, and Predictive
More informationDATA SHEET URSOFALK. Ursodeoxycholic Acid
URSOFALK - New Zealand Page 1 of 7 NAME OF DRUG DATA SHEET URSOFALK Ursodeoxycholic Acid DESCRIPTION Ursodeoxycholic acid (UDCA) is a white or almost white powder. It is practically insoluble in water,
More informationAPO-URSODEOXYCHOLIC ACID CAPSULES
APO-URSODEOXYCHOLIC ACID CAPSULES NAME OF THE MEDICINE Ursodeoxycholic Acid (UDCA) Chemical Name: 3α, 7ß-Dihydroxy-5ß-cholan-24-oic acid Structural Formula: Molecular Formula: Molecular Weight: C24H40O4
More informationYou and OCALIVA (obeticholic acid) The importance of staying on treatment
You and OCALIVA (obeticholic acid) The importance of staying on treatment What is OCALIVA? OCALIVA is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic
More informationPrimary Sclerosing Cholangitis. Bibleclass Felix Brunner
Primary Sclerosing Cholangitis Bibleclass 29.04.2015 Felix Brunner Overview Epidemiology Pathogenesis Clinical Features, Genetics, Immunology Diagnosing PSC Treatment Medications, Transplantation Cancer-Risk
More informationNASH UPDATE ON DIAGNOSTICS AND THERAPY. Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine
NASH UPDATE ON DIAGNOSTICS AND THERAPY Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine Conflicts of interest Salaried employee: of VCU Member of Board: McGuire VA Research Institute,
More informationIntercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
July 31, 2017 Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update Worldwide net Ocaliva (obeticholic acid or OCA) 2Q 2017 sales of $30.4 million AESOP Phase
More informationReview article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis
Alimentary Pharmacology and Therapeutics Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis T. H. Karlsen*,, M. Vesterhus*, & K. M. Boberg*,,
More informationTHBA Platform - Bile acid imbalance
- Bile acid imbalance Bile acids play an important role in maintaining human health by means of signaling molecules in the regulation of bile formation, liver function and metabolism. The detergent effect
More informationSOMEONE YOU CARE ABOUT HAS PBC Learn about primary biliary cholangitis (PBC), the treatment, and ways you can help
SOMEONE YOU CARE ABOUT HAS PBC Learn about primary biliary cholangitis (PBC), the treatment, and ways you can help Photograph of an actual patient and family member. What is OCALIVA (obeticholic acid)?
More informationPrimary sclerosing cholangitis (PSC) is a chronic
AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Bile Acid Changes After High-Dose Ursodeoxycholic Acid Treatment in Primary Sclerosing Cholangitis: Relation to Disease Progression Emmanouil Sinakos, 1 Hanns-Ulrich
More informationACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationObeticholic acid for the treatment of primary biliary cirrhosis Trivedi, Palak; Hirschfield, Gideon; Gershwin, M Eric
Obeticholic acid for the treatment of primary biliary cirrhosis Trivedi, Palak; Hirschfield, Gideon; Gershwin, M Eric DOI: 0./..0 License: None: All rights reserved Document Version Peer reviewed version
More informationClinical Significance of Serum Bilirubin Levels Under Ursodeoxycholic Acid Therapy in Patients With Primary Biliary Cirrhosis
Clinical Significance of Serum Bilirubin Levels Under Ursodeoxycholic Acid Therapy in Patients With Primary Biliary Cirrhosis ANNE-MARIE BONNAND, 1 E. JENNY HEATHCOTE, 2 KEITH D. LINDOR, 3 AND RENÉE EUGÉNIE
More informationUrsodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability
430 Melchor-Mendoza YK, et al., 2017; 16 (3): 430-435 ORIGINAL ARTICLE May-June, Vol. 16 No. 3, 2017: 430-435 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association
More informationPrimary biliary cirrhosis (PBC) is a rare chronic inflammatory CLINICAL LIVER, PANCREAS, AND BILIARY TRACT
GASTROENTEROLOGY 2005;128:297 303 CLINICAL LIVER, PANCREAS, AND BILIARY TRACT The Effect of Ursodeoxycholic Acid Therapy on the Natural Course of Primary Biliary Cirrhosis CHRISTOPHE CORPECHOT,* FABRICE
More informationAutoimmune Hepatitis. Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern. November 14th, 2018
Autoimmune Hepatitis Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern November 14th, 2018 AIH - Definition Manns MP J Hepatol 2015, vol 62, P 100-111 AIH - Definition Autoimmune hepatitis (AIH) is
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION OCALIVA. Obeticholic acid. 5 mg and 10 mg Tablets. Farnesoid X Receptor (FXR) Agonist
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr OCALIVA Obeticholic acid 5 mg and 10 mg Tablets Farnesoid X Receptor (FXR) Agonist OCALIVA, indicated for the treatment of primary biliary
More informationCorporate Presentation June 2017
Corporate Presentation June 2017 1 Safe Harbor & Disclaimer Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION OCALIVA. Obeticholic acid. 5 mg and 10 mg Tablets. Farnesoid X Receptor (FXR) Agonist
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr OCALIVA Obeticholic acid 5 mg and 10 mg Tablets Farnesoid X Receptor (FXR) Agonist OCALIVA, indicated for the treatment of primary biliary
More informationSarah Landes October 23, 2014
Sarah Landes October 23, 2014 A T-cell mediated inflammatory destruction of intralobular bile ducts progressively leading to cholestasis and cirrhosis 9:1 F to M ratio Mostly diagnosed between 30-60 years
More informationPutting NICE guidance into practice. Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443)
Putting NICE guidance into practice Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443) Published: April 2017 Summary Obeticholic acid is recommended as an option
More information